as of 03-27-2026 1:59pm EST
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 31.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 30.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $6.54 - $9.58 | Next Earning Date: | 03-16-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -3.39% | Revenue Growth (next year): | -15.57% |
| P/E Ratio: | 0.15 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
See how KYNB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "KYNB Kyntra Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.